Fintel reports that on December 3, 2025, BMO Capital maintained coverage of Amgen (NasdaqGS:AMGN) with a Outperform ...

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

After showing a lack of direction early in the session, stocks moved mostly higher over the course of the trading day on Wednesday. While the Nasdaq and the S&P 500 posted ...

Live Updates Get The Best SPDR S&P 500 ETF Live Earnings Coverage Like This Every Quarter Get earnings reminders, our top analysis on SPDR S&P 500 ETF, market updates, and brand-new stock ...

Amgen Inc. stock has reached a new 52-week high, hitting $345.95, marking a significant milestone for the biotechnology company. The stock is now trading just 0.99% from its 52-week high of $345.84.

William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA ...

Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 ...

Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.

AbbVie, Amgen, and IBM are among 2025’s top dividend performers, each up more than 30% while offering solid yields and steady ...

In addition to Scotiabank, Amgen also received a Buy from Piper Sandler’s David Amsellem in a report issued yesterday. However, on the same day, Truist Financial maintained a Hold rating on Amgen ...

Amgen (NASDAQ: AMGN) has outperformed the market over the past 15 years by 1.0% on an annualized basis producing an average annual return of 13.12%. Currently, Amgen has a market capitalization of ...

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not ...